Merck wins US FDA approval for expanded use of antibiotic

Merck wins US FDA approval for expanded use of antibiotic

The U.S. Food and Drug Administration on Monday approved expanded use of Merck & Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older.

FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid

REUTERS: The U.S. Food and Drug Administration on Monday approved expanded use of Merck & Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older.

The approval is based on late-stage trial results of the treatment, Zerbaxa, which showed that Merck's drug was as effective as the antibiotic meropenem.

Hospital-acquired pneumonia occurs in patients at least two-three days after being admitted or in those who are on mechanical breathing machines and have life-threatening lung infections with high mortality rates.

(Reporting by Saumya Sibi Joseph and Manojna Maddipatla in Bengaluru; Editing by Maju Samuel)

Source: Reuters

Bookmark